MX2011009824A - Derivados de pirimidina-diona fusionados como moduladores del trpa1. - Google Patents

Derivados de pirimidina-diona fusionados como moduladores del trpa1.

Info

Publication number
MX2011009824A
MX2011009824A MX2011009824A MX2011009824A MX2011009824A MX 2011009824 A MX2011009824 A MX 2011009824A MX 2011009824 A MX2011009824 A MX 2011009824A MX 2011009824 A MX2011009824 A MX 2011009824A MX 2011009824 A MX2011009824 A MX 2011009824A
Authority
MX
Mexico
Prior art keywords
tetrahydro
acetamide
dioxo
thiazol
pyrimidin
Prior art date
Application number
MX2011009824A
Other languages
English (en)
Spanish (es)
Inventor
Abraham Thomas
Neelima Khairatkar-Joshi
Sachin Sundarlal Chaudhari
Ashok Bhausaheb Kadam
Sachin Vasantrao Dhone
Sukeerthi Kumar
Indranil Mukhopadhyay
Nisha Parag Patil
Vishal Govindrao Deshmukh
Rajendra Prakash Chikhale
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MX2011009824A publication Critical patent/MX2011009824A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2011009824A 2009-03-23 2010-03-17 Derivados de pirimidina-diona fusionados como moduladores del trpa1. MX2011009824A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2211MU2009 2009-09-23
IN2212MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
US25326309P 2009-10-20 2009-10-20
IN2892MU2009 2009-12-15
IN2891MU2009 2009-12-15
US29446310P 2010-01-12 2010-01-12
US30024110P 2010-02-01 2010-02-01
PCT/IB2010/000553 WO2010109287A1 (en) 2009-03-23 2010-03-17 Fused pyrimidine-dione derivatives as trpa1 modulators

Publications (1)

Publication Number Publication Date
MX2011009824A true MX2011009824A (es) 2012-01-25

Family

ID=42780198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009824A MX2011009824A (es) 2009-03-23 2010-03-17 Derivados de pirimidina-diona fusionados como moduladores del trpa1.

Country Status (23)

Country Link
US (1) US9000159B2 (enExample)
EP (2) EP2411393B1 (enExample)
JP (1) JP5657638B2 (enExample)
KR (1) KR20110132575A (enExample)
CN (1) CN102361873B (enExample)
AP (1) AP3280A (enExample)
AU (1) AU2010227245B2 (enExample)
BR (1) BRPI1013559A2 (enExample)
CA (1) CA2756518A1 (enExample)
CL (2) CL2011002315A1 (enExample)
DK (1) DK2411393T3 (enExample)
EA (1) EA023857B1 (enExample)
ES (2) ES2551085T3 (enExample)
IL (1) IL215178A (enExample)
MX (1) MX2011009824A (enExample)
PE (1) PE20120774A1 (enExample)
PL (1) PL2411393T3 (enExample)
PT (1) PT2411393E (enExample)
SG (1) SG174402A1 (enExample)
SI (1) SI2411393T1 (enExample)
UA (1) UA108069C2 (enExample)
WO (1) WO2010109287A1 (enExample)
ZA (1) ZA201107648B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850324A (zh) 2006-08-07 2013-01-02 硬木药品公司 吲哚化合物
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
KR101591153B1 (ko) 2010-12-20 2016-02-02 그렌마크 파머수티칼스 에스. 아. Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
WO2012172475A1 (en) 2011-06-13 2012-12-20 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using trpa1 antagonists
WO2012176143A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
CA2841417A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
MX2014001551A (es) 2011-08-09 2014-09-15 Hydra Biosciences Inc Inhibicion de canal ionico del potencial receptor transitorio a1 (trpa1).
WO2013084153A1 (en) 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
JP6182072B2 (ja) 2012-01-17 2017-08-16 Ｅａファーマ株式会社 複素環アミド誘導体及びそれを含有する医薬
AU2013273118B2 (en) 2012-06-08 2015-11-05 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
KR102164756B1 (ko) 2012-10-01 2020-10-14 오리온 코포레이션 N-프로프-2-이닐 카복스아미드 유도체 및 trpa1 길항제로서의 이의 용도
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
RU2016115093A (ru) 2013-10-15 2017-11-21 Гленмарк Фармасьютикалс С.А. Фармацевтическая композиция, содержащая антагонист trpa1 и анальгетический агент
ES2747839T3 (es) 2013-10-30 2020-03-11 Shanghai hengrui pharmaceutical co ltd Derivados de pirazolopirimidona o de pirrolotriazona, método de preparación de los mismos, y aplicaciones farmacéuticas de los mismos
CN103755705B (zh) * 2014-02-17 2017-02-15 上海佰特因医药科技有限公司 一种天然产物四甲基尿酸的全合成方法
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
CN105001170A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
AU2018305633B2 (en) * 2017-07-28 2022-11-24 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing pyrimidone heteroaryl derivative and intermediate of pyrimidone heteroaryl derivative
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
CR20240352A (es) * 2022-02-03 2024-09-18 De Shaw Res Llc Compuestos de uracilo sustituidos por n3 como inhibidores de trpa1
JP2025510646A (ja) 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物
CN114656473B (zh) * 2022-04-27 2023-09-29 成都施贝康生物医药科技有限公司 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656472B (zh) * 2022-04-27 2023-07-04 成都施贝康生物医药科技有限公司 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
EP1713815A4 (en) * 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
EP1847541A4 (en) 2005-02-03 2009-12-30 Takeda Pharmaceutical CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF
US20060291462A1 (en) * 2005-06-28 2006-12-28 Utstarcom, Inc. Method and apparatus using multiple application cards to comprise multiple logical network entities
WO2007073505A2 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
TW200836743A (en) 2007-01-29 2008-09-16 Xenon Pharmaceuticals Inc Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
SI3184527T1 (sl) 2007-06-22 2020-03-31 Eli Lilly And Company Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
SG174403A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
AU2010261888A1 (en) 2009-06-18 2012-01-19 Basf Se Fungicidal mixtures
AU2010308028A1 (en) 2009-10-15 2012-04-19 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
EP2311844A1 (en) 2009-10-15 2011-04-20 Interquim, S.A. Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
KR101265451B1 (ko) 2010-07-13 2013-05-22 노파르티스 아게 옥사진 유도체, 및 신경계 장애의 치료에 있어서의 그의 용도

Also Published As

Publication number Publication date
ES2551085T3 (es) 2015-11-16
HK1166075A1 (en) 2012-10-19
EP2411393A4 (en) 2012-08-01
IL215178A (en) 2015-01-29
EP2411393A1 (en) 2012-02-01
SI2411393T1 (sl) 2014-03-31
PL2411393T3 (pl) 2014-06-30
IL215178A0 (en) 2011-12-29
AU2010227245B2 (en) 2015-09-10
CN102361873B (zh) 2014-07-09
PT2411393E (pt) 2014-02-21
HK1194742A1 (en) 2014-10-24
EA201190143A1 (ru) 2012-04-30
KR20110132575A (ko) 2011-12-08
DK2411393T3 (da) 2014-04-07
EA023857B1 (ru) 2016-07-29
UA108069C2 (uk) 2015-03-25
PE20120774A1 (es) 2012-06-27
AU2010227245A1 (en) 2011-09-22
JP5657638B2 (ja) 2015-01-21
AP2011005887A0 (en) 2011-10-31
CL2014001447A1 (es) 2014-10-17
CL2011002315A1 (es) 2012-04-09
US20140128603A1 (en) 2014-05-08
AU2010227245A2 (en) 2011-10-27
ZA201107648B (en) 2012-07-25
WO2010109287A1 (en) 2010-09-30
ES2456515T3 (es) 2014-04-22
CA2756518A1 (en) 2010-09-30
SG174402A1 (en) 2011-10-28
BRPI1013559A2 (pt) 2016-04-12
EP2411393B1 (en) 2014-01-22
US9000159B2 (en) 2015-04-07
EP2708538A1 (en) 2014-03-19
AP3280A (en) 2015-05-31
CN102361873A (zh) 2012-02-22
EP2708538B1 (en) 2015-08-12
JP2012521401A (ja) 2012-09-13

Similar Documents

Publication Publication Date Title
MX2011009824A (es) Derivados de pirimidina-diona fusionados como moduladores del trpa1.
AU735401B2 (en) Substituted 6,5-hetero-bicyclic derivatives
CA2800541C (en) Soluble guanylate cyclase activators
AU2004235907B2 (en) Fused pyrimidine derivatives with CRF activity
US6900217B2 (en) Substituted 6,5-hetero-bicyclic derivatives
MX2011009822A (es) Derivados de tienopirimidinadiona como moduladores del trpa1.
JP6285013B2 (ja) ３，５−（非）置換−１Ｈ−ピロロ［２，３−ｂ］ピリジン、１Ｈ−ピラゾロ［３，４−ｂ］ピリジン、及び５Ｈ−ピロロ［２，３−ｂ］ピラジン、ＩＴＫ及びＪＡＫ３キナーゼの阻害剤
CA2440760C (en) Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
JP2012521401A5 (enExample)
RU2011116928A (ru) Гетероциклические ингибиторы jак киназы
CA2600832A1 (en) Hiv integrase inhibitors
AU2004290626A1 (en) Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1)
WO2011114184A1 (en) Amides of heterocyclic compounds as trpa1 inhibitors
WO2010125469A1 (en) Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators
MX2011009821A (es) Derivados de isotiazolo pirimidinadiona como moduladores del trpa1.
CN114656472B (zh) 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
Gupta et al. A review on the synthesis and therapeutic potential of pyrimidine derivatives
CZ20032339A3 (cs) Farmaceutický prostředek obsahující parazolo [4,3-d]pyrimidiny a nitráty nebo thienopyrimidiny a nitráty
Mohareb et al. Discovery of new thiophene, pyrazole, isoxazole derivatives as antitumor, c-Met, tyrosine kinase and Pim-1 kinase inhibitors
CN114656480B (zh) 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
KR20030076633A (ko) 트리아조로퀴나졸린 및 피라졸로 트리아조로피리미딘유도체, 의약조성물,아데노신 에이3 수용체 친화제,안압저하제, 녹내장의 예방 및 치료를 위한 제제 및안압저하 방법
CN114671876B (zh) 新型茶碱类化合物、异构体或盐及其制备方法和用途
Abdel-Megid et al. Synthesis and Mollucicidal Activity of Some New Bicyclic and Polycyclic Pyrimidine Derivatives
RU99123368A (ru) Соединения
AU2015200071A1 (en) Bicyclic pyridines and analogs as sirtuin modulators